Researchers at the National Institutes of Health (NIH) are conducting an investigational treatment study with the HEPLISAV-B (hepatitis-B) vaccine and/or the SHINGRIX (shingles) vaccine. Eligible volunteers must have either never received treatment for their chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) OR currently be receiving ibrutinib or acalabrutinib for their CLL/SLL. Volunteers will participate in the study for 6 months.

You may be eligible for the HEPLISAV-B (hepatitis B) vaccine study if you: *(Refer to study 18-H-0145)*

- Have a diagnosis of CLL or SLL and meet one of the following criteria
  - Have never received treatment for CLL or SLL
  - OR
    - Are currently receiving ibrutinib or acalabrutinib for at least 6 months
- Are at least 18 years old
- Are not receiving IVIG (intravenous immunoglobulin)
- Are not receiving other immunosuppressing agents (e.g. steroids, rituximab)

You may be eligible for the SHINGRIX (shingles) vaccine study if you: *(Refer to study 19-H-0001)**

- Have a diagnosis of CLL or SLL and meet one of the following criteria
  - Have never received treatment for CLL or SLL
  - OR
    - Are currently receiving ibrutinib or acalabrutinib for at least 6 months
- Are at least 18 years old
- Are not receiving IVIG (intravenous immunoglobulin)
- Are not receiving other immunosuppressing agents (e.g. steroids, rituximab)
- Have never received the SHINGRIX vaccine before (SHINGRIX vaccine study only)
- Have not had shingles in the past 12 months
- Have not received the ZOSTAVAX (live shingles) vaccine in the past 12 months

The NIH Clinical Center is America’s Research Hospital and is located in Bethesda, Maryland, on the Metro Red line (Medical Center stop).

To learn how to participate, contact:
Office of Patient Recruitment 1-800-411-1222
cp-prpl@cc.nih.gov
TTY for the deaf or hard of hearing 1-866-411-1010
Online:  [https://go.usa.gov/xmyRE](https://go.usa.gov/xmyRE)  
**[https://go.usa.gov/xmyRy](https://go.usa.gov/xmyRy)**